Kush Fansiwala

Kush Fansiwala

Auto-generated profile, based on publicly available information

Kush Fansiwala

Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at UCLA , Los Angeles, CA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Radiology: Cardiothoracic Imaging
Verified
Journal Article
Closed access
MKMark Kaminetzky
Mark Kaminetzky
WMWilliam Moore
William Moore
KFKush Fansiwala
Kush Fansiwala
JBJames S. Babb
James S. Babb
DKDavid Kaminetzky
David Kaminetzky
JKJane P. Ko
Jane P. Ko
Background Understanding pulmonary embolism (PE) rate and contributing comorbid, clinical, laboratory, and imaging characteristics may aid in management of pro-thombotic events in COVID-19 (COVID+)...

25 May 2024 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
KFKush Fansiwala
Kush Fansiwala
ESEllen J Spartz
Ellen J Spartz
ARAndrew R Roney
Andrew R Roney
MKMary R Kwaan
Mary R Kwaan
JSJenny S Sauk
Jenny S Sauk
BLBerkeley N Limketkai
Berkeley N Limketkai
Background: The era of biologics is associated with declining rates of surgery for Crohn’s disease (CD), but the impact on surgery for stricturing CD is unknown. Our study aimed to assess nationwide trends in bowel resection surgery for obstruction in CD since the introduction of infliximab for CD in 1998. Methods: Using the Nationwide Inpatient Sample, we performed a nationwide analysis, identifying patients hospitalized for CD who underwent bowel resection for an indication of obstruction between 1998 and 2020 (era of biologics). Longitudinal trends in all CD-related resections and resection for obstruction were evaluated. Multivariable logistic regression identified patient and hospital characteristics associated with bowel resection surgery for obstruction. Results: Hospitalizations for all CD-related resections decreased from 12.0% of all hospitalizations in 1998 to 6.9% in 2020, while hospitalizations for CD-related resection for obstructive indication increased from 1.3% to 2.0%. The proportion of resections for obstructive indication amongst all CD-related bowel resections increased from 10.8% in 1998 to 29.1% in 2020. In the multivariable models stratified by elective admission, the increasing year was associated with risk of resection for obstructive indication regardless of urgency (nonelective model: odds ratio, 1.01; 95% CI, 1.00-1.02; elective model: odds ratio, 1.06; 95% CI, 1.04-1.08). Conclusions: In the era of biologics, our findings demonstrate a decreasing annual rate of CD-related bowel resections but an increase in resection for obstructive indication. Our findings highlight the effect of medical therapy on surgical rates overall but suggest limited impact of current medical therapy on need of resection for stricturing disease.

4 September 2023 in Nutrition in Clinical Practice
Verified
Journal Article
Open access
KFKush Fansiwala
Kush Fansiwala
NSNeha D. Shah
Neha D. Shah
KMKelly A. McNulty
Kelly A. McNulty
MKMary R. Kwaan
Mary R. Kwaan
BLBerkeley N. Limketkai
Berkeley N. Limketkai
Crohn's disease (CD), a form of inflammatory bowel disease, involves chronic inflammation within the gastrointestinal tract. Intestinal strictures and fistulas are common complications of CD with varying severity in their presentations. Modifications in oral diet or use of exclusive enteral nutrition (EEN) are common approaches to manage both stricturing and fistulizing disease, although supporting research evidence is generally limited. In the preoperative period, there is strong evidence that EEN can reduce surgical complications. Parenteral nutrition (PN) is often utilized in the management of enterocutaneous fistulas, given that oral diet and EEN may potentially increase output in proximal fistulas. This narrative review highlights the current practices and evidence for the roles of oral diet, EEN, and PN in treatment and management of stricturing and fistulizing CD.

5 December 2023 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
PDF file
KFKush Fansiwala
Kush Fansiwala
ARAlison Rusher
Alison Rusher
BSBrandon Shore
Brandon Shore
HHHans H Herfarth
Hans H Herfarth
EBEdward Barnes
Edward Barnes
SCShannon Chang
Shannon Chang
Antibiotics are a cornerstone in management of intra-abdominal abscesses in Crohn’s disease (CD). Yet, the optimal route of antibiotic administration is poorly studied. We aimed to compare surgical and nonsurgical readmission outcomes for patients hospitalized for intra-abdominal abscesses from CD discharged on oral (PO) or intravenous (IV) antibiotics. Data for patients with CD hospitalized for an intra-abdominal abscess were obtained from 3 institutions from January 2010 to December 2020. Baseline patient characteristics were obtained. Primary outcomes of interest included need for surgery and hospital readmission within 1 year from hospital discharge. We used multivariable logistic regression models and Cox regression analysis to adjust for abscess size, history of prior surgery, history of penetrating disease, and age. We identified 99 patients discharged on antibiotics (PO = 74, IV = 25). Readmissions related to CD at 12 months were less likely in the IV group (40% vs 77% PO, P = .01), with the IV group demonstrating a decreased risk for nonsurgical readmissions over time (hazard ratio, 0.376; 95% confidence interval, 0.176-0.802). Requirement for surgery was similar between the groups. There were no differences in time to surgery between groups. In this retrospective, multicenter cohort of CD patients with intra-abdominal abscess, surgical outcomes were similar between patients receiving PO vs IV antibiotics at discharge. Patients treated with IV antibiotics demonstrated a decreased risk for nonsurgical readmission. Further prospective trials are needed to better delineate optimal route of antibiotic administration in patients with penetrating CD.

9 January 2023 in Gastro Hep Advances
Verified
Journal Article
Open access
KFKush Fansiwala
Kush Fansiwala
NRNeha Rajpal
Neha Rajpal
SNShaya Noorian
Shaya Noorian
ADAnoushka Dua
Anoushka Dua
PCPo-Hung Chen
Po-Hung Chen
BLBerkeley N. Limketkai
Berkeley N. Limketkai
Gastrointestinal (GI) disorders represent a significant burden on United States healthcare, but research assessing the relative contribution of individual GI disorders is lacking. We aimed to determine the relative impact of various GI conditions, as compared to non-GI conditions, on US hospital-related healthcare utilization. Hospitalization data from 2016 to 2018 were obtained from the Nationwide Readmissions Database. Outcomes included length of stay, hospital charges, 30-day readmissions, and death. Multivariable regression models evaluated each outcome, while adjusting for patient and hospital characteristics. Patients hospitalized for each GI indication were compared to individuals hospitalized for non-GI conditions. 5,344,145 patients with GI and 68,901,595 patients with non-GI indications for hospitalization were included in our study. All GI indications were associated with increased odds for 30-day readmission compared to non-GI indications, with the highest being gastroparesis (adjusted odds ratio, 2.15; 95% confidence interval [CI], 2.09–2.22). Upper GI cancer had the highest relative increase in length of stay (2.31 days, 95% CI 2.20–2.42) and total charges ($23,441, 95% CI $21,296–25,587). Upper GI cancer, pancreatic cancer, and gallbladder/biliary cancer were associated with the highest odds of death. GI malignancies contributed significantly to utilization and death, possibly from advanced stage at hospitalization and systemic effects of malignancy. The high GI-specific readmission rates highlight the chronicity of GI conditions and the importance of optimizing digestive health to prevent recurrent admission.

23 August 2023 in Military Medicine
Verified
Journal Article
Open access
PDF file
KFKush Fansiwala
Kush Fansiwala
YQYingzhi Qian
Yingzhi Qian
PLPeter S. Liang
Peter S. Liang
Risk factors for gastric cancer in the United States are not well understood, especially in populations with a low proportion of immigrants. We conducted a matched case–control study in a Veteran Affairs Medical Center to identify risk factors for gastric cancer. Gastric cancer patients and age- and sex-matched controls were identified in a 1:4 ratio from January 1, 1997 to October 31, 2018. Demographic, medical, endoscopic, and histologic data were extracted. We performed conditional logistic regression to estimate odds ratios and 95% CIs for associations between potential risk factors and gastric cancer. Most gastric cancer cases were diagnosed on initial endoscopy (71.4%). Of these, the most common presenting stage was stage IV (40.8%). Risk factors for gastric cancer included Black and Asian race and never or current (compared to former) drinkers, although Helicobacter pylori eradication and pernicious anemia were associated with decreased risk. The high proportion of late-stage gastric cancer diagnoses highlights the need for improved risk stratification as well as screening and surveillance protocols in the U.S. population. Racial disparities among veterans in an equal-access system necessitate further investigation into the etiology of these disparities.